Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$175.8B
4,417M shares
52-week range
$35.12 – $64.16
15% from low
Exchange
NYSE
ADRC
P/S (TTM)
0.5
EV / FCF (TTM)
5.5
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
www.novonordisk.comNo one on the platform currently holds NVO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,397,121 | $124.8M |
| Bridgewater Associatesas of 2025-09-30 | 138,947 | $7.7M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-17 | $0.5792 | 2026-08-25 |
| 2026-03-30 | $1.2174 | 2026-04-08 |
| 2025-08-18 | $0.5843 | 2025-08-26 |
| 2025-03-31 | $1.1426 | 2025-04-08 |
| 2024-08-16 | $0.5169 | 2024-08-26 |
| 2024-03-22 | $0.9293 | 2024-04-02 |
| Execution date | Ratio |
|---|---|
| 2023-09-20 | 2-for-1 |
| 2014-01-09 | 5-for-1 |
| 2007-12-17 | 2-for-1 |
No one on the platform has traded NVO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 33.6% | 52.7% | 165.9% | — | — | — |
| Rev. Growth % | 6.4% | 19.5% | ||||
| Profit Margin % | 33.1% | 33.8% | 33.7% | |||
| Free Cash Flow Margin % | 9.4% | 26.7% | 28.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +19.1% on the P/E track.
At today's price, your expected annual return is +22.6% on the P/E track.
At today's price, your expected annual return is +26.3% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $301.4B | -2.1% | $22.24 | $19.34–$25.39 | 1.8× | 6 |
| 2027 | $305.6B | +1.4% | $21.89 | $20.14–$23.32 | 1.8× | 7 |
| 2028 | $324.8B | +6.3% | $23.90 | $21.87–$27.43 | 1.6× | 4 |
| 2029 | $349.5B | +7.6% | $27.18 | $24.87–$31.19 | 1.4× | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $0.82 | $0.96 | +17.1% |
| 2026-05-06 | $0.87 | $1.04 | +19.5% |
| 2026-02-03 | $0.90 | $1.00 | +11.1% |
| 2025-11-05 | $0.77 | $1.02 | +32.5% |
| 2025-08-06 | $0.93 | $0.97 | +4.3% |
| 2025-05-07 | $0.92 | $0.92 | +0.0% |
| 2025-02-05 | $0.88 | $0.91 | +3.4% |
| 2024-11-06 | $0.87 |
| $0.88 |
| +1.4% |
| $186.9B |
| — |
| GSKGSK plc | $51.08 | +1.71% | $102.3B | — |
| MRKMerck & Co., Inc. | $149.50 | +1.79% | $369.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$VKTX I am but a bull on $VKTX. 🐂 Big Pharma has dry powder + looming patent cliffs. Strategic names to watch: $MRK, $AZN, $NVO. No confirmed M&A. Biotech carries significant clinical, regulatory, competitive & valuation risk. This is speculation, not financial advice. DYODD.
View on StockTwits ↗
$VKTX I can sell for $200 per share if $NVO wish to buy us.
View on StockTwits ↗
$NVO only thing that saves bulls tomorrow is news Otherwise more bleeding
View on StockTwits ↗
$NVO The foundation holds a majority stake, so they don't need to buy shares—that’s what the buyback is for. It’s carried out by a bank on Novo’s behalf, involving around 220,000 shares daily on the Danish market. Neither the foundation nor the management is overly concerned with the share price, since a takeover isn't possible; consequently, they face no pressure to inflate the valuation or appease Wall Street. From their perspective, a low price is actually great because it means they can buy shares more cheaply...
View on StockTwits ↗
$NVO how much more man.. they dumped it so bad it has been down since forever.. even hims goes up sometimes this is down from 70 to 36 in a year. I guess downfall is inevitable
View on StockTwits ↗
$NVO Remember the foundation owns almost 30% of all stock and we know they are not selling, they should be buying and creating a Volkswagen type moment taking shares off the market, someone on here mentioned that earlier today I don’t think anything like that could happen here unless the foundation aquired a massive amount of outstanding shares and we had a life changing moment of amazing news on some new type drug but we can all dream
View on StockTwits ↗
$NVO , The lion share of NVO pipeline is weight loss/diabetes. Did they take too long to pivot to other products knowing the patent expiration coming and rapidly growing competition?
View on StockTwits ↗
$NVO $LLY $VKTX lol, keep buying novo "cheap" shares bulls, 0 IQ.
View on StockTwits ↗
$NVO it’s pe is under 10 and company is still growing . Don’t get fear mongering and believe in the numbers. I’m holding my shares despite being 10% down. No biggies
View on StockTwits ↗
$VKTX the CNBC talking head table all but stopped short of dialing $NVO up on the phone during the live broadcast to push them on considering a b/o here.
View on StockTwits ↗
$NVO , is there any chance NOVO goes private? NVO holdings owns 29% of shares.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.